SyncAI.news, a Varaisys broadcasting
SMILESGNN: Interpretable Clinical Toxicity Prediction via SMILES-Graph Cross-Attention Fusion
QM

Quang Minh Nguyen, Thuy Quynh Nguyen, Duc Minh Le, Ho Nhat Minh Nguyen, Thanh Long Dai Doan, Trong Nghia Nguyen

· 1 min read

ResearcharXiv cs.LG

SMILESGNN: Interpretable Clinical Toxicity Prediction via SMILES-Graph Cross-Attention Fusion

arXiv:2609.28553v1 Announce Type: new Abstract: Drug toxicity prediction is critical for reducing late-stage attrition in drug discovery, yet remains challenging due to severe class imbalance, scaffold-based generalization, and the clinical need for interpretable predictions. Single-modality approaches-SMILES Transformers or graph neural networks capture complementary aspects of molecular structure, while sequence-only models cannot directly provide graph-attributed explanations. We present SMILESGNN, a multimodal architecture that fuses a SMILES Transformer encoder and a GATv2 graph encoder via cross-attention, and SMILESGNN-PT, a variant using a ChemBERTa-2 pretrained backbone. The design retains an explicit graph branch within the predictive pipeline, supporting GNNExplainer-based analysis of substructures associated with toxic predictions. On ClinTox, SMILESGNN achieves AUC-ROC 0.987 and F1 0.906 with only 0.4M parameters, performing competitively with a strong SMILESTransformer and a larger ChemBERTa-2/GATv2 concat-fusion baseline. On Tox21 (12 tasks), SMILESGNN-PT obtains mean AUC-ROC 0.750, comparable to ChemBERTa-2 alone and the same-backbone concat-fusion baseline. Overall, the results suggest that cross-attention is a practical fusion alternative that preserves competitive predictive performance while enabling graph-based interpretability support.

Original source

This story was published by arXiv cs.LG and written by Quang Minh Nguyen, Thuy Quynh Nguyen, Duc Minh Le, Ho Nhat Minh Nguyen, Thanh Long Dai Doan, Trong Nghia Nguyen. SyncAI.news shows a preview; the complete article is on the publisher's site.

Read the full story on arxiv.org

Similar News